Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
FBLG FibroBiologics	$0.59 -0.1%	$0.64	$0.53 ▼ $4.41	$24.66M	-0.74	507,551 shs	996,183 shs
RNTX Rein Therapeutics	$1.27 +12.4%	$1.37	$1.04 ▼ $4.40	$29.60M	1.31	69,061 shs	39,885 shs
RVPH Reviva Pharmaceuticals	$0.54 +3.6%	$0.48	$0.30 ▼ $4.28	$36.62M	-0.05	2.69 million shs	2.69 million shs
SBFM Sunshine Biopharma	$1.40 -1.4%	$1.49	$1.17 ▼ $3.90	$6.38M	1.45	42,027 shs	18,885 shs

Ten Starter Stocks For Beginners to Buy Now

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
FBLG FibroBiologics	0.00%	+2.63%	-10.36%	-27.33%	-62.75%
RNTX Rein Therapeutics	0.00%	+6.37%	-10.56%	-38.05%	+126,999,900.00%
RVPH Reviva Pharmaceuticals	0.00%	-0.28%	+25.20%	-47.72%	-36.47%
SBFM Sunshine Biopharma	0.00%	-6.03%	-9.68%	-2.78%	-53.64%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
FBLG FibroBiologics	2.7164 of 5 stars	3.6	3.0	0.0	0.0	1.1	2.5	0.6
RNTX Rein Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
RVPH Reviva Pharmaceuticals	2.6964 of 5 stars	3.6	1.0	0.0	0.0	2.3	3.3	0.6
SBFM Sunshine Biopharma	2.1271 of 5 stars	3.5	3.0	0.0	0.0	1.1	0.8	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
FBLG FibroBiologics	3.20	Buy	$13.00	2,108.63% Upside
RNTX Rein Therapeutics	2.00	Hold	N/A	N/A
RVPH Reviva Pharmaceuticals	3.13	Buy	$7.17	1,230.86% Upside
SBFM Sunshine Biopharma	3.00	Buy	$15.00	971.43% Upside

Current Analyst Ratings Breakdown

Latest SBFM, FBLG, RNTX, and RVPH Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/19/2025	RNTX Rein Therapeutics	Brookline Capital Management Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Hold
8/18/2025	RVPH Reviva Pharmaceuticals	Roth Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$7.00 ➝ $3.00
8/18/2025	RVPH Reviva Pharmaceuticals	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$3.00
8/15/2025	RVPH Reviva Pharmaceuticals	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
8/15/2025	RVPH Reviva Pharmaceuticals	Maxim Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$5.00 ➝ $2.00
8/5/2025	FBLG FibroBiologics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00 ➝ $12.00
8/4/2025	FBLG FibroBiologics	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$16.00
7/29/2025	FBLG FibroBiologics	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$16.00
7/9/2025	FBLG FibroBiologics	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$16.00
6/27/2025	RVPH Reviva Pharmaceuticals	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$3.00
6/17/2025	FBLG FibroBiologics	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$16.00

(Data available from 8/24/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
FBLG FibroBiologics	N/A	N/A	N/A	N/A	$0.08 per share	N/A
RNTX Rein Therapeutics	N/A	N/A	$0.45 per share	2.84	$0.43 per share	N/A
RVPH Reviva Pharmaceuticals	N/A	N/A	N/A	N/A	$0.02 per share	N/A
SBFM Sunshine Biopharma	$34.87M	0.18	N/A	N/A	$9.10 per share	0.15

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
FBLG FibroBiologics	-$11.16M	-$0.36	0.00	N/A	N/A	N/A	-710.25%	-118.02%	11/11/2025 (Estimated)
RNTX Rein Therapeutics	-$62.88M	-$2.69	0.00	N/A	N/A	N/A	-141.11%	-33.83%	N/A
RVPH Reviva Pharmaceuticals	-$29.92M	-$0.65	0.00	N/A	N/A	N/A	N/A	-259.17%	N/A
SBFM Sunshine Biopharma	-$5.13M	-$150.88	N/A	∞	N/A	-17.35%	-26.04%	-20.72%	11/3/2025 (Estimated)

Latest SBFM, FBLG, RNTX, and RVPH Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2025	Q2 2025	RNTX Rein Therapeutics	-$0.22	-$0.28	-$0.06	-$0.28	N/A	N/A
8/14/2025	Q2 2025	RVPH Reviva Pharmaceuticals	-$0.15	-$0.12	+$0.03	-$0.12	N/A	N/A
8/12/2025	Q2 2025	SBFM Sunshine Biopharma	-$0.11	-$0.39	-$0.28	-$0.39	$12.10 million	$9.41 million
7/31/2025	Q1 2025	FBLG FibroBiologics	-$0.11	-$0.12	-$0.01	-$0.12	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
FBLG FibroBiologics	N/A	N/A	N/A	N/A	N/A
RNTX Rein Therapeutics	N/A	N/A	N/A	N/A	N/A
RVPH Reviva Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
SBFM Sunshine Biopharma	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
FBLG FibroBiologics	N/A	0.93	0.93
RNTX Rein Therapeutics	N/A	0.86	1.39
RVPH Reviva Pharmaceuticals	N/A	0.90	0.54
SBFM Sunshine Biopharma	N/A	5.00	2.66

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
FBLG FibroBiologics	N/A
RNTX Rein Therapeutics	90.89%
RVPH Reviva Pharmaceuticals	63.18%
SBFM Sunshine Biopharma	41.98%

Insider Ownership

Company	Insider Ownership
FBLG FibroBiologics	20.80%
RNTX Rein Therapeutics	5.10%
RVPH Reviva Pharmaceuticals	27.18%
SBFM Sunshine Biopharma	0.10%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
FBLG FibroBiologics	10	41.89 million	33.18 million	N/A
RNTX Rein Therapeutics	9	23.31 million	22.12 million	N/A
RVPH Reviva Pharmaceuticals	5	68.00 million	49.52 million	Optionable
SBFM Sunshine Biopharma	3	4.56 million	4.55 million	Not Optionable

SBFM, FBLG, RNTX, and RVPH Headlines

Recent News About These Companies

Sunshine Biopharma Launches NIOPEG (R) Into $10 Billion Biologics Market - Morningstar

July 3, 2025 | morningstar.comM

SBFM - Sunshine Biopharma Inc News - Morningstar

July 3, 2025 | morningstar.comM

Sunshine Biopharma, Inc. (SBFM) - Yahoo Finance

July 2, 2025 | finance.yahoo.com

Sunshine Biopharma Launches NIOPEG(R) Into $10 Billion Biologics Market

July 2, 2025 | accessnewswire.comA

Sunshine Biopharma Unit Launches Generic Anticonvulsant In Canada: Retail Sees ‘Huge Potential’

June 11, 2025 | msn.com

Sunshine Biopharma Launches Generic Gabapentin for Neuropathic Pain in the Canadian Segment of the Global $1.92 Billion Market

June 11, 2025 | accessnewswire.comA

Sunshine Biopharma Reports 2025 First Quarter Results, Revenues Up 18% Over Same Period Last Year

May 15, 2025 | accessnewswire.comA

Sunshine Biopharma Inc.: Sunshine Biopharma Launches Generic Lurasidone for Schizophrenia in the Canadian Sector of the Global $1.2 Billion Market

May 6, 2025 | finanznachrichten.de

Sunshine Biopharma Launches Generic Lurasidone for Schizophrenia in the Canadian Sector of the Global $1.2 Billion Market

May 6, 2025 | accessnewswire.comA

Sunshine Biopharma launches Everolimus in Canada

April 22, 2025 | markets.businessinsider.com

Sunshine Biopharma Launches Everolimus In Canada, an Oncology Drug with an Estimated Global Market of $2.5 Billion

April 21, 2025 | accessnewswire.comA

Sunshine Biopharma Inc. Announces Closing of $2.46 Million Registered Direct Offering

April 3, 2025 | accessnewswire.comA

This Pharma Stock Is Gaining Major Steam Ahead Of Opening Bell

April 2, 2025 | msn.com

Sunshine Biopharma Inc. Announces $2.46 Million Registered Direct Offering Priced at the Market Under Nasdaq Rules

April 2, 2025 | accessnewswire.comA

Sunshine Biopharma Stock Shoots Higher On Encouraging Data From mRNA-Based Liver Cancer Drug

April 2, 2025 | benzinga.com

Sunshine Biopharma Announces Positive Results of mRNA Therapy for Cancer

April 2, 2025 | finance.yahoo.com

Sunshine Biopharma Reports Revenue of $34.9M in Fiscal 2024, Up 45% From Last Year

April 1, 2025 | accessnewswire.comA

Sunshine Biopharma signs agreement for rights to market two generic antibiotics

March 24, 2025 | msn.com

Sunshine Biopharma Expands Presence in the $53.9 Billion Global Antibiotics Market with the Acquisition of Marketing Rights for Two New Antibiotics in Canada

March 24, 2025 | accessnewswire.comA

Sunshine Biopharma Inc.: Sunshine Biopharma Acquires Rights to Launch Two Gastrointestinal Drugs in the Canadian $200 Million Market

March 10, 2025 | finanznachrichten.de

New MarketBeat Followers Over Time

Media Sentiment Over Time

SBFM, FBLG, RNTX, and RVPH Company Descriptions

FibroBiologics NASDAQ:FBLG

$0.59 0.00 (-0.05%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$0.60 +0.01 (+1.09%)

As of 08/22/2025 07:54 PM Eastern

FibroBiologics, Inc. operates as a cell therapy, regenerative medicine company. It is developing a pipeline of treatments and potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials. It holds 150+ U.S. and internationally issued patents/patents pending across various clinical pathways, including disc degeneration, orthopedics, multiple sclerosis, psoriasis, wound healing, reversing organ involution, and cancer. FibroBiologics, Inc. was incorporated in 2021 and is based in Houston, Texas.

Rein Therapeutics NASDAQ:RNTX

$1.27 +0.14 (+12.39%)

As of 08/22/2025 03:59 PM Eastern

Rein Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of a novel class of therapeutics for the treatment of cancer and other diseases. It focuses on its lead product candidate, ALRN-6924, which is a cell-permeating peptide that disrupts the interaction of p53 suppressors MDM2 and MDMX with tumor suppressor p53 to reactivate tumor suppression in non-mutant, or wild-type, p53 cancers. The company was founded by Gregory L. Verdine, Rosana Kapeller, Huw M. Nash, Joseph A. Yanchik III, and Loren David Walensky on August 6, 2001 and is headquartered in Austin, TX.

Reviva Pharmaceuticals NASDAQ:RVPH

$0.54 +0.02 (+3.56%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$0.54 0.00 (-0.65%)

As of 08/22/2025 07:56 PM Eastern

Reviva Pharmaceuticals Holdings, Inc., a biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, inflammatory, and cardiometabolic diseases. The company's lead product candidate comprises brilaroxazine (RP5063) for the treatment of various neuropsychiatric indications, including schizophrenia, bipolar disorder, major depressive disorder, attentiondeficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia and Alzheimer's disease, and Parkinson's disease psychosis; in clinical development respiratory indications, such as pulmonary arterial hypertension and idiopathic pulmonary fibrosis; and in preclinical development for the treatment of psoriasis. It is also developing RP1208 for the treatment of depression and obesity. Reviva Pharmaceuticals Holdings, Inc. was founded in 2018 and is headquartered in Cupertino, California.

Sunshine Biopharma NASDAQ:SBFM

$1.40 -0.02 (-1.41%)

Closing price 08/22/2025 03:49 PM Eastern

Extended Trading

$1.46 +0.07 (+4.64%)

As of 08/22/2025 04:43 PM Eastern

Sunshine Biopharma, Inc., a pharmaceutical company, focuses on the research and development of life-saving medicines in various therapeutic areas, including oncology and antivirals in the United States and Canada. It operates in two segments, Prescription Generic Pharmaceuticals and Nonprescription Over-The-Counter Products. The company is developing SBFM-PL4, a protease inhibitor for the treatment of SARS coronavirus infections; Adva-27a, a small chemotherapy molecule to treat pancreatic cancer; and K1.1 mRNA, a lipid nano-particle for liver cancer. It also offers Essential 9, an amino acids capsules; Calcium-Vitamin D supplement under the Essential Calcium-Vitamin D brand name; and L-Citrulline and Taurine products. In addition, the company provides various generic prescription drugs for osteoporosis, cardiovascular, antipsychotic, antibacterial, hypertension, anti-inflammatory, allergy, antibiotic, central nervous system, diabetes, urology, antifungal, antimalarial, oncology, gastroenterology, and anticonvulsant indications. Sunshine Biopharma, Inc. is headquartered in New York, New York.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time